Quantification and clinical relevance of brain atrophy in multiple sclerosis: a review.
about
The effect of disease modifying therapies on brain atrophy in patients with relapsing-remitting multiple sclerosis: a systematic review and meta-analysisA Personalized Approach in Progressive Multiple Sclerosis: The Current Status of Disease Modifying Therapies (DMTs) and Future PerspectivesUse of Advanced Magnetic Resonance Imaging Techniques in Neuromyelitis Optica Spectrum DisorderRevisiting brain atrophy and its relationship to disability in multiple sclerosisMRI evaluation of grey matter atrophy and disease course in multiple sclerosis: an overview of current knowledge.Brain and cord myelin water imaging: a progressive multiple sclerosis biomarker.Longitudinal study of vision and retinal nerve fiber layer thickness in multiple sclerosis.Mechanisms of cognitive impairment in cerebral small vessel disease: multimodal MRI results from the St George's cognition and neuroimaging in stroke (SCANS) study.Walking Speed and Brain Glucose Uptake are Uncoupled in Patients with Multiple SclerosisPredictive value of different conventional and non-conventional MRI-parameters for specific domains of cognitive function in multiple sclerosis.The Effect of Disease-Modifying Drugs on Brain Atrophy in Relapsing-Remitting Multiple Sclerosis: A Meta-AnalysisClinical relevance of brain atrophy assessment in multiple sclerosis. Implications for its use in a clinical routine.The effect of disease-modifying therapies on brain atrophy in patients with clinically isolated syndrome: a systematic review and meta-analysis.Fully automated open-source lesion mapping of T2-FLAIR images with FSL correlates with clinical disability in MSLower levels of glutathione in the brains of secondary progressive multiple sclerosis patients measured by 1H magnetic resonance chemical shift imaging at 3 T.A comprehensive approach to the segmentation of multichannel three-dimensional MR brain images in multiple sclerosis.Stress-induced brain activity, brain atrophy, and clinical disability in multiple sclerosis.Neuroprotective effects of testosterone treatment in men with multiple sclerosis.Role of executive functions in prospective memory in multiple sclerosis: Impact of the strength of cue-action association.Sex differences in resting-state functional connectivity in multiple sclerosis.Automated determination of brain parenchymal fraction in multiple sclerosis.White matter volume is decreased in the brain of patients with neuromyelitis optica.Unique topographic distribution of greyhound nonsuppurative meningoencephalitis.Pronounced focal and diffuse brain damage predicts short-term disease evolution in patients with clinically isolated syndrome suggestive of multiple sclerosis.Alexithymia and impaired facial affect recognition in multiple sclerosis.Multiple sclerosis and cognitive decline: is ApoE-4 a surrogate marker?[18F]FSPG-PET reveals increased cystine/glutamate antiporter (xc-) activity in a mouse model of multiple sclerosis.A comparison of brain magnetic resonance imaging lesions in multiple sclerosis by race with reference to disability progression
P2860
Q26824991-CF65DD58-4A8F-4599-B240-F060DDBEB58FQ28068709-ABD27F01-74C8-4AC7-83B6-7D152A7AFD25Q28085378-FA372613-818E-41D4-A64C-1BC3A4255D6BQ28729953-4D7F945E-AF6D-4E5C-9873-25B07B9E606EQ30769070-A1E266F8-9E95-4E41-921A-DD51F2886E7DQ31027249-711F1FA8-CE65-48D8-A3A5-44A639A5D407Q33983613-8A8E0149-A908-4B28-94B1-3991B2934193Q34683943-B21ED1E4-7D37-44CB-88DE-84D73404F21EQ35094371-13F0ACF5-A993-4C17-8CF4-6B81FE770B8FQ35221948-F27737FC-019E-4272-BB51-F09BC2462AEBQ35959784-0D4855A4-CA2F-4CB2-B292-47C1DBAA9AF4Q35997017-7B298361-D4AE-4624-8886-B7E015F8C94CQ36211674-1C3D0D64-DFAE-49ED-9BF2-D8A94494DA69Q36515844-B7A7D83C-7023-45B2-A096-166A0B7C4EEFQ37059931-86E1A516-FAE2-4EED-92B4-175A66E1576FQ37184546-A80A3C7E-0E49-4D7A-876D-1EA1112A9E03Q37451337-8AF96B82-4214-471A-97F2-2A7574528070Q37634705-A305E1A9-2B5C-4DB5-9CE3-687881E55F56Q38399619-066C77BE-5C0F-4280-9424-D03479087F67Q43647987-6D582321-EAF6-463B-8A9A-3CFDE6A6C3BAQ43845286-E0AF2696-D490-4138-A10E-016D6372639AQ48376954-776C3088-3671-4938-A3AE-4164C2979DA8Q48458188-0A6BACA6-FC0A-44ED-BCB2-165AFC815AB0Q49089264-0BD7BB8C-FC46-41EC-82DC-D04692F4A880Q50636296-C0C226B7-EF93-43EB-8AD6-EB7385C8856AQ53315711-4A876C05-BF1A-4700-AD09-7376723B3631Q55174845-BB792735-1253-484F-8C21-2643C3BBEB75Q58763252-B293B34C-6139-4941-8613-B57D3E735582
P2860
Quantification and clinical relevance of brain atrophy in multiple sclerosis: a review.
description
2009 nî lūn-bûn
@nan
2009 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
name
Quantification and clinical relevance of brain atrophy in multiple sclerosis: a review.
@ast
Quantification and clinical relevance of brain atrophy in multiple sclerosis: a review.
@en
type
label
Quantification and clinical relevance of brain atrophy in multiple sclerosis: a review.
@ast
Quantification and clinical relevance of brain atrophy in multiple sclerosis: a review.
@en
prefLabel
Quantification and clinical relevance of brain atrophy in multiple sclerosis: a review.
@ast
Quantification and clinical relevance of brain atrophy in multiple sclerosis: a review.
@en
P2860
P1433
P1476
Quantification and clinical relevance of brain atrophy in multiple sclerosis: a review
@en
P2093
Blandine Grassiot
Gilles Defer
P2860
P2888
P304
P356
10.1007/S00415-009-5108-4
P577
2009-04-08T00:00:00Z
P6179
1012430609